Merck & Co., Inc.

Antinausea regimens compared in patients after chemotherapy

Published in Managed Care Business Week, May 10th, 2005

An investigational study evaluated the effect of an antiemetic regimen including Emend (aprepitant; Merck & Co., Inc.) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients with that of the standard regimen only.

The results were published in the April 18, 2005, Journal of Clinical Oncology.

Researchers wrote, "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide±doxorubicin or epirubicin. Patients were randomly assigned to either an aprepitant [APR] regimen (day 1, APR 125 mg, ondansetron (OND) 8 mg, and dexamethasone 12 mg before chemotherapy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Managed Care Business Week

Source: Managed Care Business Week (2005-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry